NCT07803744RecruitingPhase 1
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity. Participation in this study will last about 8 weeks, including screening and follow-up.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 1 Sept 2026
- Start date
- 11 Sept 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity, Type 1 diabetes
- NCT number
- NCT07803744
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 18
- From 11 Sept 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery
Other illness
- Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists
Other
- Participants who have a known clinically significant gastric emptying abnormality
Who the study is looking for
- Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening
- Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening
- Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Pharmacology of Miami Coordinator of this site? Confirm its status | Miami | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.